Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
One thing going for Takeda is that in Japan annual yields on borrowing is about 0.34 % whereas in the states it 3.8% and Europe is 0.89 % so Takeda would be borrowings at a very cheap rate.
Mergers can add to the value of shares so its not a bad thing. In any case smaller companies have been known to buy out larger peers. It may still be a takeover.
This is beginning to look very interesting takeda have position in shire. I would love to know what Japanese banks Takeda are talking to concerning any potential buyout of shire. It would be great if a suitor from the states jumped in then the share would skyrocket. Wishful thinking by me!
I have read that it would be more of a merger than an actual takeover. if that happened it would make it a lot more difficult for one of the massive pharma companies to come in at a later date to try and buy it. Do you have any idea what a merger would do to the share price?
Didnt one of the latest rns notice under 8.3 say takeda had acquired 1% interest in shire? Also takeda is similar size to shire so it is likely to be a merger rather than a takeover. Get your house ready to be taken away Tom :-)
I�m wondering whether this is all being staged to try and flush out a potential big pharma company into entering the bidding because like you say takeda can�t afford to buy shire, it seems ridiculous to even attempt to. None of it makes much sense and we could all end up with a share price right down to �25 if it doesn�t come off. Then i will be ****ed off!
I think the problem lies with Takeda's inability to fund this deal. Their SP is down 9% in last 2 days which dents their ability to issue paper but also tells them that their shareholders are not so keen. Takeda is smaller than Shire so funding a $55bn deal is probably beyond them. Thus share price is only at �34.5. But this could accelerate other potential buyers. I would put my house on Takeda not buying Shire but I do believe that another suitor will appear.
Considering shire is the subject of a possible takeover this share price is an absolute pittance but then again nothing surprises me with this company.
Can anyone in plain English please explain the significance of all these RNS's. Do i take it that Takeda have been buying shares in SHP or just shorting them for some reason. Any help very welcome.
Looking at the latest updates from shire on buys and sells, these big boys made tonnes of money yesterday.
Funny how these brokers are giving low 40s price target now that there is a bid possibility. Before bid rumours these fkers were issuing targets of �50 plus. Goes to show they wanted PIs to buy then and get stuck with crashing share price and now they want PIs to sell on the cheap (so to regret when price goes up with potential bid offers).
I have lived in Japan and seen first hand how the corporate operation works ... I would find it rather odd for a Japanese company to moot a deal and then follow through as it would show a huge loss of face ... I cannot think of a Japanese company that has done a volte-face ... Just a thought -- BB --
The market is doing its job. After a sustained period of poor performance, drugmaker Shire Plc has attracted the attention of Takeda Pharmaceutical Co. A full-blown takeover would be highly ambitious -- perhaps too ambitious -- for the Japanese suitor. But Shire�s defenses are weak and the other big pharmaceutical groups are on the prowl. Shire stock has fallen 45 percent in the last 15 months, mostly the result of the poorly received acquisition of Baxalta Inc. in June 2016. Management credibility is weak. Even after gaining on Takeda�s interest, the shares, at about 36 pounds, trade at a big discount to peers on both earnings and Ebitda multiples. UBS analysts have a price target of 40.95 pounds on the stock. Takeda says it is considering an approach. There are no talks let alone a concrete offer. The stated logic for a deal would be to strengthen the Japanese group�s oncology, gastroenterology and neuroscience businesses and boost its presence in the U.S. Takeda also covets Shire�s rare disease franchise. It�s hard to see big opportunities to cut costs here. Shire�s is a peculiar therapeutic mix and, as UBS notes, a bidder could jeopardize Shire�s favorable tax rate too. The hemophilia franchise also faces stiff competition. In reality, the attraction is that Shire is cheap and vulnerable -- something which other bidders will see. The challenge for Takeda is structuring a deal. The suitor has a market value of 4.4 trillion yen ($42 billion) compared with Shire�s 28 billion pounds ($40 billion) before takeover interest emerged. Use a three-month volume-weighted average share price, and the valuation is a little higher. Those relative sizes mean Takeda would need to structure an offer largely in its own stock. If Shire shareholders weren�t keen on, or able, to hold shares that trade in Japan, Takeda might have to provide an additional U.K. listing -- as Dana Inc., of the U.S. is proposing in its bid for GKN Plc�s automotive business. It�s all quite fiddly. Unfortunately for Takeda, it may suffer a first-mover disadvantage. Who else might see an opportunity? Novartis AG has a strong balance sheet and will soon receive $13 billion from the sale of its share in a consumer health joint venture to partner GlaxoSmithKline Plc. That said, Novartis has said its M&A strategy is about bolt-ons and this would be way too big for that. Paris-based Sanofi is acquisitive in the hemophilia area, although its leverage is creeping up with recent deals and would probably also have to resort to funding its offer in stock too. Abbvie Inc. is another possibility -- it�s just had a major setback with one of its main pipeline drugs, and tried to buy Shire in 2014. Put a 33 percent takeover premium on Shire�s undisturbed price, add net debt, and a full-blown takeover would cost about $73 billion. But with Shire expected to make about $7.6 billion i
I think you forgot to take your medication.....
A potential acquisition of London-listed Shire by Takeda Pharmaceutical was greeted with investor scepticism about it merits on Thursday, with shares in the Japanese drug maker tumbling 7 percent. Takeda, currently worth some $39 billion, is smaller than Shire, a rare disease specialist which saw its stock jump 16 percent to be valued at some $45 billion after the Japanese firm said it was in a "preliminary and exploratory stage" of considering a bid. That similarity in size had raised the question whether the damage to Takeda's finances would be worth the boost to its portfolio and pipeline. "The impression left by the news is that the acquisition would be an overreach," said Mizuho Securities analyst Hiroshi Tanaka in a note to clients. Any deal is expected to involve some form of equity, whether that be a share swap or a share issue, analysts also said, noting a share issue could be highly dilutive for Takeda shareholders. Takeda said an acquisition of Shire, which also sells treatments for attention deficit disorder, could create a global biopharmaceutical leader, boost its position in the United States and in the fields of oncology, gastrointestinal diseases and neuroscience. But some analysts also doubted whether Shire's treatments for haemophilia and other rare diseases would benefit Takeda and thought that any deal should be more targeted. "We think neuroscience assets alone, which Shire said are under strategic review, would be a realistic target, but we find it hard to imagine Takeda acquiring all of Shire," said UBS analyst Atsushi Seki. "We think the possibility of it making a proposal is very low, but its share price will likely be under pressure from concern over potential dilution."
Hey buddy, welcome back to the chat board. I am a young ish man and your story worries me! Can u help me find a wealthy queen before my duck goes all wrinkly and sagy pls? Morning all, lets see if it goes back down to 30 or move up. Either way, interesting few weeks/months ahead. Good luck
The story goes like this; there was a little girl. She went to school, studied hard and did sports. With time , after doing what she was supposed to do, she started to blossom and curve up. She started to be noticed by boys and man, getting compliments, invites to events....soon did she learn how to carry her self and benefit. First boyfriend was younger than her, she learned what she needed fast and went through him quickly. Second boyfriend was her age, slightly more work but more education too. Third, forth ,... every next older and more experienced than previous. She was getting brainier and more knowledgeable but time was ticking. She wanted to settle and put her feet up. She started socialising with Suzy K. Known mach maker. Result, sugar daddy made an offer without sampling first although she had her nickers down to her knees. She was so happy, so was Suzy K. who had prearranged cutt of the pie. But family leaned on sugar daddy and wedding was off. She was distrott but continued looking and dating. After few respectful boyfriends, every subsequent greater than previous, but no sugar daddy in sight. She got frustrated, found sugar daddy�s son and proposed him. After getting her commitment that she will cook and clean and perform on events and bead, he said yes. Little did she know what she got her self in, boy(husband now) had a shaky job, no ambition and she had to pay for wedding, he wanted grande one. She realised she�d passed her pick and is entering decline zone of her life. She couldn�t divorce ( to expensive), she was getting tired, saggy, visibly aged and could not fight off competition, younger girls, reflecting in job stagnation and ever diminishing social life. Out of blue comes new sugar daddy and whisper in her ear he might marry her and her useless husband together. Instinctively she reached for her panties....she was sweet, bright, hard working girl and now... In short summary of today: 800 points up, 400 down 150 up, 150 down, almost all on autopilot. Total 1500 points greater than 1000 points on Dow the other week (for me). Now that I�m not so much long only anymore, I�d be happy with �30 or sub and with �45 and above. Btw second sugar daddy knew about first one but thinks he has bigger duck. Common self-delusion with megalomaniacs, ups she had a duck too when she married, is she really well respected maturing lady or a old queen? Looking back, well who cares
These are not late (executed) trades, just reported late as allowed under LSE rules...SP has fallen quite a bit since U.K. close on the NASDAQ but tomorrow, who knows, but a lower start than �35 it would appear. ATB, Scfc
Finally we have something a little more concrete rather than rumour. Takeda has made a formal announcement and listed the reasons why they think Shire would be a good buy for them. Pfizer may well trump them though. At the very least today has shown that yes there are companies interested in buying Shire and it is not quite the basket case you have been making them out to be for the past year now.
yes, it will be interesting to watch tomorrow. but broker rating mean nothing for shire. they have had average rating of �50 plus over the last few months / weeks and yet it was trading at low 30s.
Some monster after hour trades gone through couple a couple 4mill x2 10 mill and HL have one for 41mill New broker rating at 4100 RSN out What will tomorrow bring
Takeda Pharm Co Ltd Rule 8 Announcement to Shareholders RNS Number : 3110J Takeda Pharmaceutical Company Ltd 28 March 2018 28 March 2018 Takeda Pharmaceutical Company Limited Notice to Shareholders Regarding UK Takeover Code Disclosure Requirements On 28 March 2018, Takeda Pharmaceutical Company Limited ("Takeda") made an announcement regarding a possible offer by Takeda for Shire plc ("Shire") (the "Possible Offer"). Takeda wishes to direct the attention of its shareholders to certain disclosure requirements applicable to the Possible Offer. The relevant disclosure requirements are set out in Rule 8 of the UK City Code on Takeovers and Mergers, which is published and administered by the UK Takeover Panel. In particular, Rule 8.3 of the Takeover Code requires that any person who is interested (directly and/or indirectly) in 1% or more of any class of relevant security of any party to the possible offer must make (a) an Opening Position Disclosure and (b) a Dealing Disclosure if they deal in any relevant security of any party to the possible offer during an offer period. Takeda's ordinary shares are relevant securities for the purposes of this offer period. Full details are set out at the end of this announcement. Further information about the Takeover Panel's disclosure regime is available at: http://www.thetakeoverpanel.org.uk/disclosure. If any Takeda shareholder has any questions on these disclosure requirements, the Takeover Panel's Market Surveillance Unit will be happy to answer them and should be contacted on +44 (0)20 7638 0129. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. In particular, no offer of securities shall be made in the United States absent registration under the US Securities Act of 1933, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the US Securities Act of 1933. Disclosure requirements of the Code Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to
did your long negate the earlier profitable short?
Agreed. It is a strange one given its own size/strictness on M&A and Shire have seemingly confirmed it has had no formal contact of any possible deal...this is possibly why the shares are now off nearly 9% from the initial big jump earlier today. Who knows, other than more volatility...Scfc
Takeda have until 5pm on the 25th april to make an offer or to go away so expect a rollercoaster ride for the shares in the next few weeks